# Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Source: https://onco.cc/trials/nct05909397/  
OnCo record `nct05909397` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Vepdegestrant and Palbociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.

## Summary

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer is a phase 3 interventional study registered as NCT05909397 by Pfizer, with 59 participants enrolled, started 2023-08-09 and due to reach its primary completion in 2026-12-30. Interventions recorded: Vepdegestrant (ARV-471/PF-07850327), Palbociclib and Letrozole.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05909397
- Phase: 3
- Setting: A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)
- Sponsor: Pfizer
- Enrolled: 59

## Sources

- ClinicalTrials.gov NCT05909397: https://clinicaltrials.gov/study/NCT05909397

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Palbociclib](https://onco.cc/drugs/palbociclib/), [Vepdegestrant](https://onco.cc/drugs/vepdegestrant/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct05909397.json